MUTZ; Michael

Patent Applications and Registrations

Patent applications and USPTO patent grants for MUTZ; Michael.The latest application filed is for "crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof".

Company Profile

1.35.58

MUTZ; Michael - Lorrach DE
MUTZ; Michael - Basel CH
Mutz; Michael - Freiburg DE
Mutz; Michael - Freiburg i.Br. DE
Mutz; Michael - Freilburg DE
Mutz; Michael - Freiberg DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Trademarks

Patent Activity

Patent	Date
Crystalline Forms Of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile And Formulations Thereof App 20220162170 - BULLOCK; Joseph Paul ; et al.	2022-05-26
Hemifumarate Salt Of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-be- Nzyl]-azetidine-3-carboxylic Acid App 20210323915 - CISZEWSKI; Lech ; et al.	2021-10-21
Salts and solid forms of a monobactam antibiotic Grant 10,919,887 - Aubin , et al. February 16, 2	2021-02-16
Salts And Solid Forms Of A Monobactam Antibiotic App 20180273522 - AUBIN; Eric ; et al.	2018-09-27
Hemifumarate Salt Of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-be- Nzyl]-azetidine-3-carboxylic Acid App 20180118678 - CISZEWSKI; Lech ; et al.	2018-05-03
Substituted Indole Derivatives App 20150284364 - Bieri; Nicole ; et al.	2015-10-08
Hemifumarate Salt Of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-be- Nzyl]-azetidine-3-carboxylic Acid App 20150175536 - CISZEWSKI; Lech ; et al.	2015-06-25
Plymorphic forms of deferasirox (ICL670A) Grant 8,946,272 - Mutz February 3, 2	2015-02-03
Stabilized Amorphous Forms of Imatinib Mesylate App 20140323495 - Goncalves; Elisabete ; et al.	2014-10-30
Crystalline form K of imatinib mesylate Grant 8,846,706 - Mutz September 30, 2	2014-09-30
Organic compounds Grant 8,710,216 - Hoehn , et al. April 29, 2	2014-04-29
Organic compounds Grant 8,680,146 - Jordine , et al. March 25, 2	2014-03-25
Salt forms of 4-(4-Methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-- 2-ylamino)phenyl]-benzamide App 20140051853 - Burger; Hans Michael ; et al.	2014-02-20
Organic Compounds App 20140051766 - Jordine; Guido ; et al.	2014-02-20
Crystalline form F of imatinib mesylate Grant 8,633,213 - Mutz January 21, 2	2014-01-21
Hemifumarate Salt Of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-be- Nzyl]-azetidine-3-carboxylic Acid App 20140005162 - CISZEWSKI; Lech ; et al.	2014-01-02
Crystalline form I of imatinib mesylate Grant 8,592,440 - Mutz November 26, 2	2013-11-26
Acid Addition Salts, Hydrates and Polymorphs of 5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-is- oxazole-3-carboxylic Acid Ethylamide and Formulations Comprising These Forms App 20130296556 - Drysdale; Martin James ; et al.	2013-11-07
Plymorphic Forms of Deferasirox (ICL670A) App 20130267572 - Mutz; Michael	2013-10-10
Organic compounds Grant 8,530,522 - Jordine , et al. September 10, 2	2013-09-10
Stabilized Amorphous Forms of Imatinib Mesylate App 20130225598 - Goncalves; Elisabete ; et al.	2013-08-29
F, G, H, I and K Crystal Forms of Imatinib Mesylate App 20130224288 - Mutz; Michael	2013-08-29
Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-- 2-ylamino)phenyl]-benzamide Grant 8,513,256 - Burger , et al. August 20, 2	2013-08-20
Crystalline form G of imatinib mesylate Grant 8,507,515 - Mutz August 13, 2	2013-08-13
Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-iso-propyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-i- soxazole-3-carboxylic acid ethylamide and formulations comprising these forms Grant 8,487,095 - Drysdale , et al. July 16, 2	2013-07-16
Polymorphic forms of deferasirox (ICL670A) Grant 8,436,030 - Mutz May 7, 2	2013-05-07
Quinazolinone Derivatives Useful As Vanilloid Antagonists App 20130060029 - Chen; Weichun ; et al.	2013-03-07
Stabilized Amorphous Forms of Imatinib Mesylate App 20130022672 - Goncalves; Elisabete ; et al.	2013-01-24
Quinazolinone derivatives useful as vanilloid antagonists Grant 8,349,852 - Chen , et al. January 8, 2	2013-01-08
Organic Compounds App 20120322789 - HOEHN; Pascale ; et al.	2012-12-20
Crystal Form H of Imatinib Mesylate for Pharmaceutical Use App 20120226038 - Mutz; Michael	2012-09-06
Polymorphic Forms Of Deferasirox (icl670a) App 20120203007 - Mutz; Michael	2012-08-09
Acid Addition Salts, Hydrates And Polymorphs Of 5-(2,4-dihydroxy-5-iso-propyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-i- Soxazole-3-carboxylic Acid Ethylamide And Formulations Comprosing These Forms App 20120172592 - Drysdale; Martin James ; et al.	2012-07-05
Crystal form H imatinib mesylate for pharmaceutical use Grant 8,198,289 - Mutz June 12, 2	2012-06-12
Crystal form of N-benzoyl-staurosporine Grant 8,198,435 - Hoehn , et al. June 12, 2	2012-06-12
Salt forms of 4-(4-Methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino)phenyl]-benzamide App 20120142697 - Burger; Hans Michael ; et al.	2012-06-07
Crystal form of epothilone B and use in pharmaceutical compositions Grant 8,178,566 - Kusters , et al. May 15, 2	2012-05-15
Hemifumarate Salt Of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-be- Nzyl]-azetidine-3-carboxylic Acid App 20120115840 - Ciszewski; Lech ; et al.	2012-05-10
Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-is- oxazole-3-carboxylic acid ethylamide and formulations comprising these forms Grant 8,163,747 - Drysdale , et al. April 24, 2	2012-04-24
Polymorphic forms of deferasirox (ICL670A) Grant 8,153,672 - Mutz April 10, 2	2012-04-10
F, G, H, I and K Crystal Forms of Imatinib Mesylate App 20120015955 - Mutz; Michael	2012-01-19
F, G, H, I and K Crystal Forms of Imatinib Mesylate App 20120015027 - Mutz; Michael	2012-01-19
Salt And Polymorphs Of A Kinesin Inhibitor Compound App 20110275685 - Mutz; Michael ; et al.	2011-11-10
Organic Compounds App 20110229501 - Jordine; Guido ; et al.	2011-09-22
Organic Compounds App 20110218248 - Jordine; Guido ; et al.	2011-09-08
F, G, H, I and K Crystal Forms of Imatinib Mesylate App 20110171301 - Mutz; Michael	2011-07-14
Crystalline form F of Imatinib mesylate Grant 7,893,076 - Mutz February 22, 2	2011-02-22
Delta and epsilon crystal forms of Imatinib mesylate Grant 7,879,860 - Mutz February 1, 2	2011-02-01
5-amino-3-(2',3'-di-o-acetyl-beta-d-ribofuranosyl)-3h-thiazolo[4,5-d] Pyrimidin-2-oce Salts And Crystalline Forms App 20100286081 - Mutz; Michael ; et al.	2010-11-11
Quinazolinone Derivatives Useful as Vanilloid Antagonists App 20100197705 - Chen; Weichun ; et al.	2010-08-05
Stabilized Amorphous Forms Of Imatinib Mesylate App 20100178336 - Goncalves; Elisabete ; et al.	2010-07-15
Crystal Form Of Epothilone B And Use In Pharmaceutical Compositions App 20100160393 - Kusters; Ernst ; et al.	2010-06-24
Acid Addition Salts, Hydrates and Polymorphs of 5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-is- oxazole-3-carboxylic Acid Ethylamide and Formulations Comprising These Forms App 20100093732 - Drysdale; Martin James ; et al.	2010-04-15
Polymorphis of a known thiophenecarboxylic acid dodecahydrocyclopenta (a) phenanthrenyl ester Grant 7,683,048 - Jordine , et al. March 23, 2	2010-03-23
Polymorphic Forms Of Deferasirox (icl670a) App 20100056590 - Mutz; Michael	2010-03-04
Crystalline Forms Of Zoledronic Acid App 20100056481 - Glausch; Alexandra ; et al.	2010-03-04
Fermentative Preparation Process For And Crystal Forms Of Cytostatics App 20090326239 - Hofmann; Hans ; et al.	2009-12-31
Organic Compound App 20090137552 - Hoehn; Pascale ; et al.	2009-05-28
Organic Compounds Comprising a Glycopyrrolium Salt App 20080268040 - Mutz; Michael	2008-10-30
Delta and Epsilon Crystal Forms of Imatinib Mesylate App 20080254116 - Mutz; Michael	2008-10-16
Salt Forms of 4- (4-Methylpiperazin-1-Ylmethyl) -N- [4-Methyl-3- (4-Pyridin-3-Yl) Pyrimidin-2-Ylamino) Phenyl]- Benzamide App 20080249104 - Burger; Hans Michael ; et al.	2008-10-09
Fermentative preparation process for and crystal forms of cytostatics App 20070197611 - Hofmann; Hans ; et al.	2007-08-23
Fermentative preparation process for and crystal forms of cytostatics Grant 7,101,702 - Hofmann , et al. September 5, 2	2006-09-05
Polymorphis of a known thiophenecarboxylic acid dodecahydrocyclopenta (a) phenanthrenyl ester App 20060166954 - Jordine; Guido ; et al.	2006-07-27
Fermentative preparation process for and crystal forms of cytostatics App 20040142990 - Hofmann, Hans ; et al.	2004-07-22
Fermentative preparation process for and crystal forms of cytostatics Grant 6,656,711 - Hofmann , et al. December 2, 2	2003-12-02
Fermentative preparation process for and crystal forms of cytostatics App 20030220379 - Hofmann, Hans ; et al.	2003-11-27
Fermentative preparation process for and crystal forms of cytostatics App 20030194787 - Hofmann, Hans ; et al.	2003-10-16
Fermentative preparation process for and crystal forms of cytostatics App 20020165256 - Hofmann, Hans ; et al.	2002-11-07
Fermentative preparation process for and crystal forms of cytostatics Grant 6,194,181 - Hofmann , et al. February 27, 2	2001-02-27

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.